← Eichor
Condition: Advanced Non Small Cell Lung Cancer Her2 Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Non Small Cell Lung Cancer Her2 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06114511Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or M
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT06749860Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HE
Phase 2 · 17 location(s) · Boehringer Ingelheim · NCT07486817PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Phase 2 · 1 location(s) · Yongchang Zhang · NCT04144569A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06430437First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations i
Phase 1/Phase 2 · 94 location(s) · Bayer · NCT05099172Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell L
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT05751018Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC
Phase N/A · 22 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT07356544A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · 285 location(s) · Bayer · NCT06452277A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 102 location(s) · DualityBio Inc. · NCT05150691The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Phase N/A · 23 location(s) · Daiichi Sankyo · NCT06809764A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Phase 1/Phase 2 · 42 location(s) · BlossomHill Therapeutics · NCT06706076
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.